An early U.S. feasibility study for transfemoral delivery of the Intrepid self-expanding bioprosthetic valve for transcatheter mitral valve replacement (TMVR) showed “excellent” device function in moderate to severe mitral regurgitation (MR) patients at high surgical risk, with no mortality or stroke at 30 days, according to new study findings.